Building a Chemical Toolkit for Probing Biological Networks
Quantifying biomolecules in their natural setting can give a portrait of a biological system; but to elucidate the connectivity in these systems-the intricate relationships between nodes in a network-and to understand the spatial and temporal dynamics of these relationships, we need a means to precisely disrupt the system. Chemical probes, including small molecule modulators of biological function, allow us to selectively perturb individual members of a biological system in a virtually natural state of the system. Using these tools, we can further our understanding of not only the function(s) of our target biomolecule, but also the connectivity of the system as a whole. [1] [2] [3] Depending on the biological question at hand, the search for a small molecule probe generally follows one of two general approaches: reverse chemical genetics or forward chemical genetics. [4] Reverse chemical genetics places emphasis on target engagement and typically involves biochemical or biophysical methods. These types of binding assays assume that a considerable number of compounds that directly bind the target will have some functional effects, which will be confirmed and characterized downstream. Forward chemical genetics places an emphasis on a functional effect or phenotypic consequence in a cellular setting, with the knowledge that the target(s) and mechanism(s) of action of the small molecule will be determined in follow-up studies.
While HTS methods for both target-based and phenotype-based approaches have been around for many years, in the past decade, we have seen the fruits of those technological developments, as well as their application to new target classes. Recent efforts in HTS assay development for chemical probe discovery show a significant effort towards designing more robust assays as well as combinations of well-established HTS principles. [5] Recent efforts in HTS development have not been focused merely on pushing the limits of screening throughput or format miniaturization, but increasing the quality, quantity, and scope of measurable content. Here we discuss some of the most recent probe discovery efforts using novel biochemical and cell-based assay approaches.
Biochemical and Biophysical Assays
Target-focused screening methods are ideal for discovering small molecule inhibitors of a defined enzymatic activity or a specific bimolecular interaction. These assays typically involve highly purified and structurally stable proteins, but recent efforts show adaptations of these assay formats to accommodate screening target molecules in complex settings, including cell lysate ( Figure 1 ).
Fluorescence polarization (FP) assays have been around for decades and are highly amenable to high throughput screening for a variety of target classes. Several years ago, this venerated principle for high-throughput binding detection was leveraged to detect functional outcomes, namely inhibition of enzymatic activity through fluorescence polarizationactivity-based protein profiling (fluopol-ABPP). [6, 7] In what is essentially a highthroughput competition assay, purified, active enzymes are screened against potential inhibitors in the presence of a fluorescence-conjugated natural ligand mimetic, which acts as a competitor molecule and provides an increased FP signal when enzyme activity is uninhibited. Recently, Chang et al., applied this approach in the development of P11 as an inhibitor of two different yet structurally similar platelet-activating factor acetylhydrolases (PAFAH1b2 and PAFAH1b3), which are implicated but relatively uncharacterized in a variety of disease states. [8] Using recombinant mouse PAFAH1b2 and a serine hydrolase specific ABPP probe, a rhodamine-conjugated fluorophosphonate that covalently binds to serine residues in the active site of the enzyme, the authors screened over 300,000 compounds from an NIH curated library with a 0.37% hit rate. After filtering out hits with reported activity in literature and removing false positives identified by using the same ABPP probe in a gel based competition assay, a group of tetrahydropyridines emerged, with one compound, P11, exhibiting the highest potency with an IC 50 of 0.8 μM. Follow on studies demonstrate the molecule as an inhibitor of PAFAH1b2 and PAFAH1b3 exclusively and that P11 inhibition of PAFAH1 activity in a cancer cell model results in significantly decreased cell survival. [8] While the exploration of PAFAH1 inhibition as a therapeutic strategy is ongoing, this work demonstrates the incredible scale and utility of the fluopol-ABPP for novel enzymatic probe discovery.
Förster resonance energy transfer (FRET) assays are powerful high throughput techniques used to discover inhibitors or stabilizers of biomolecular interactions. [9] In a recent example, a FRET assay involving purified, full length CBFβ-SMMHC and the purified Runt domain of RUNX1, Illendula et. al. identified the compound AI-4-57, which disrupts the protein-protein interaction (PPI) of these molecules with an IC50 of 22 μM and prevents the acute myeloid leukemia-associated fusion protein CBFβ-SMMHC from modulating the activity of the RUNX1 transcription factor. [10] Further study of this molecule lead to the development of AI-10-49, a multivalent analog that restores normal RUNX1 transcriptional activity and delays leukemia in mice, demonstrating both the power of a chemical probe in testing therapeutic strategies and the utility of a high throughput FRET assay to discover modulators of PPIs with relevant in vivo activity. More recently, FRET methodology has been coupled with time resolved fluorometry in a technique called time-resolved FRET (TR-FRET), which uses the long-lived fluorescence of lanthanide metals as FRET donors to increase signal-to-noise ratio in a FRET assay. Whys et al. use the TR-FRET approach for screening methyl binding domains in order to identify molecules that could interfere with the DNA binding function. [11] Using a purified, His-tagged methyl binding domain of MBD2 (MBD2-MBD) and a terbium-labeled anti-His-tag antibody as the FRET donor and a FAM labeled hairpin-forming C-methylated oligonucleotide as the FRET acceptor, the authors returned 4 hits with IC 50 values in the 10-100 nM range from a screen of 1280 commercially available compounds. The authors adapted this screen to serve as a counter screen for specificity by using purified, His-tagged SP1 (a transcription factor) and unmethylated oligos, which showed that the four initial hits, two DNA intercalators and two other bioactives, nonspecifically block protein-oligo interactions. Though no true probes of MBD2-MBD were found in this pilot screen, this proof of concept work demonstrates highthroughput approaches for discovery of probes against a new class of epigenetic regulators through TR-FRET. Recently Schulze et al. have devised a novel use of TR-FRET reagents for a high-throughput protein stabilization assay in cell lysate with another epigenetic systems protein, BRD4, demonstrating proof of concept with a well characterized probe of the protein, JQ1. [12, 13] The assay uses the principle that small-molecule bound protein will have increased stability to indirectly detect binding events in live cells through the identification of increased intracellular protein concentration levels. Compound-treated cell lines overexpressing N-and C-terminal epitope tagged BRD4 are lysed with buffer containing TR-FRET antibodies against the N-and C-terminal epitope tags of the protein to enable protein quantification without protein purification, an added advantage for unbiased probe discovery against targets which are difficult to purify. [12] Small molecule microarrays (SMMs) are another HTS assay equally suited for purified targets and targets in cell lysate, which allows for the screening of a range of targets from the traditional to the challenging. We point the reader to a review of recent successful applications of this technology extensively used in our laboratory for concrete examples, but, will highlight that this approach is especially attractive for screening compounds against difficult targets, such as proteins residing in complexes and intrinsically disordered proteins. [14] For example, transcription factors, many of which are intrinsically disordered when purified away from interacting partners, are attractive as potential therapeutic targets and have been considered 'undruggable.' Recently, BRD32048, an inhibitor of a prostate cancer-associated transcription factor, ETV1, was discovered using SMMs screened against cell lysates containing epitope-tagged ETV1. [15, 16] Mechanistic studies involving BRD32048 suggested a new avenue for modulating the function of recalcitrant transcriptional targets through inhibition of vital posttranslational events such as acetylation. This story demonstrates that unbiased binding screens involving proteins in cell lysate can give rise to compounds with novel or unexpected mechanisms of modulation from a single screen.
To this point, we have focused on chemical screening approaches that rely on some aspect of fluorescence for detection of binding events. While these approaches are easily scalable to test compound libraries over 10 6 in size, follow-up assays often reveal significant false positive rates. [17] In reaction to this reality, some have turned to fragment-based screening methods, where hundreds of chemical fragments are screened in a high fidelity biophysical assay, such as nuclear magnetic resonance spectroscopy (NMR). Though fragment-based NMR screening is much lower in throughput and requires considerable downstream chemistry, this technique gives true positives for target binding even for weak binders and, most importantly, continues to see great success in both drug and probe discovery against many diverse targets. [18] [19] [20] However, only a handful of years ago, the limits of throughput in a fragment-based screening workflow were challenged in what Wu et. al. term HTS by NMR. [21] In this workflow for discovering antagonists of protein-protein interactions, a peptide mimetic library for screening is assembled based on positional scanning to greatly reduce the amount of NMR runs necessary to test a large number of fragment combinations. The details on the theory behind this approach can be found in the 2013 paper, but, briefly, mixtures of diverse compounds of equal fragment length which share one common fragment in a given position are assembled and tested together in a single reaction mixture, under the assumption that the fixed position fragment is responsible for the majority of the chemical shift detected through NMR. In their proof of concept, this allows a library of 100 fragments representing 10 6 potential structures to be tested robustly by NMR using just 300 compounds. This technique has the added advantages of reducing the burden of downstream combinatorial chemistry found in typical small molecule fragment library screening campaigns due to the common backbone of fragments in a peptide-mimetic library. Most importantly, the authors demonstrate the utility of this workflow for de novo discovery of three novel, selective, and cellularly active EphA4 receptor inhibitors with IC 50 values in the single to double-digit micromolar range using purified EphA4 LBD in an HTS by NMR workflow.
Mass spectrometry (MS) is another label-free technique that has the added advantages of quantitation and identification of target peptides, chemical species, and the substrates and products of peptides under scrutiny. Historically, MS has been reserved for later stages of probe development pipelines, as sample runs typically require liquid chromatography (LC) separation of reaction mixtures and are time intensive processes. Recently, though, MS has been pushed to the front of the discovery pipeline through the availability of new sample processing technology platforms, like RapidFire Solid Phase Extraction (SPE) from Agilent, which eliminates the need for liquid chromatography and is compatible with plate-based formats with rapid sample processing time. [22, 23] These high throughput mass spectrometry (HTMS) approaches are gaining more traction in the field where established 
Cell-Based Phenotypic Assays
Cell based high-throughput assays evaluate compounds based on their modulation of a precisely defined phenotype often using a luminescence or fluorescence readout ( Figure 2 ). Examples of commonly assayed phenotypes include gene expression (e.g. luciferase reporter assays, Luminex L1000, or fluorescent protein-gene product fusions), [26] [27] [28] protein localization (e.g. intracellular vs. extracellular or cytoplasm vs. nucleus), [29] [30] [31] or cell morphology (e.g. changes in organelles or the overall cell). [32] [33] [34] [35] All of these approaches have enabled identification of small molecules that modulate a given phenotype, but do not directly provide insight into the mechanism of action for a molecule or even the precise target(s) the molecule acts upon. As these approaches are typically target-agnostic, complex studies to identify the direct target(s) and mechanism(s) of action are often required for cellbased HTS assay hits. [36, 37] Despite this drawback, these assays provide a powerful means for discovering probe molecules of disease phenotypes and physiological pathways with cellular activity, even without a hypothesis of which nodes in a network should be targeted to induce the phenotype of interest.
Isa et al. recently described a novel HTS assay that exploits a well established biological mechanism of HER2 regulation, the internalization of HER2 for sorting to acidic endosomes and lysosomes for its degradation. [29] The authors used the emerging HaloTag labeling technology in combination with an acidic pH-activatable probe to search from compounds that induce internalization of the receptor. Using 17-AAG, a HSP-90 inhibitor known to induce HER2 internalization, and NH 4 Cl, which reverses signal of the probe through intravesicular alkalization, the authors validated the assay format and demonstrated minimal nonspecific signal. The assay monitored the change in fluorescence signal between internalized HER2 signal and NH 4 Cl treatment (ΔF = F before − F after ) providing an excellent Z factor (>0.5) and high signal-to-noise ratio (44.6) . Using a 384-well format the authors screened a library of ~155,000 small molecules to identify small molecules that induced internalization and degradation. They chose to retest the top ~0.1% compounds in quadruplicate, resulting in 16 hits with >15% activity. One compound led to a 50% decrease of HER2 in 1h at 5 μM. This robust assay format can potentially be adapted to other receptors with similar internalization mechanisms and could be considered as a complement to the current antibody-based campaigns seen in drug discovery campaigns.
In another recent HTS report, Tang et al. [38] developed a high-content cell based assay to identify small molecules antagonists of AXL. This assay relies on antibody labeling to quantify pAKT in the presence of compound after stimulation with either GAS6 ligand or MAB154 agonist, screening this receptor tyrosine kinase activity in a cell-based format may present advantages over a biophysical format using purified components, as AXL has unique activation behaviors dependent on spatial presentation of GAS6. [39] The sensitivity of the assay is relatively strong (with a 4-fold pAKT induction in H1299 cell line) and the parallel mechanisms of receptor activation can aid in identifying the hits that inhibit AXL kinase activity rather than GAS6 binding. This screening approach may have the potential to identify novel and specific AXL pathway inhibitors by preventing AXL activation.
Fu et al. demonstrate the value of thoroughly understanding the biological mechanisms governing a phenotypic state when designing a cell-based assay with their recent work related to endoplasmic reticulum (ER) stress. [30] The authors sought to discover small molecules that are able to correct ER stress, a phenomena believed to be involved in a number of human pathologies ranging from diabetes and obesity to cancer and inflammation, by exploiting the trafficking of two ER-associated proteins. In a normal, low stress state ATF6, a transcription factor that controls chaperone gene expression, is repressed by abundant chaperone binding, whereas ASGR1, a membrane-associated protein, is highly produced and secreted. Inversely, a high stress state (reduced folding capacity in the ER) traffics ATF6 out of ER through the Golgi and retains ASGR1 in the ER until chaperone levels are restored. The authors designed two complementary assays where they fused Luciferase to the luminal domain of AFL6 or to the truncated ASRG1 lacking the membrane-anchoring domain, using a second luciferase in both assays as an internal control. Using these two systems to monitor ER stress through luciferase activity, they have identified azoramide, which protects cells from induced ER stress. The authors determined the IC 50 for the AFL6 system to be ~1.3 μM and the EC 50 for the secreted ASRG1 to be 8.8 μM. This screening campaign was performed in 96-well format, but it should be easily scalable to 384-well format since the amount of media needed for luciferase measurements is relatively small (10 μL).
Finally a recent HTS report uses a niche-based, two-cell culture system to screen compounds against multiple myeloma (MM) cells to identify compounds that overcome stromal resistance, a term used to describe the survival benefit conferred to multiple myeloma cells by neighboring bone marrow stromal cells (BMSC) resulting in resistance to standard chemotherapy. [40] The authors designed a high-throughput assay using GFPexpressing MOLP5 cells co-cultured with primary BMSC. The readout involved monitoring cell viability by measuring changes in fluorescence intensity. Screening a library of ~25,000 compounds they identified BRD9876 (IC 50 ~2.2 μM in MM1S cells) that inhibits various MM cell lines, overcomes BMSC-conferred resistance and displays selectivity over hematopoietic progenitors. The authors then employed an extraordinary battery of functional genomic and cellular assay that identified Kinesin-5 (Eg5) as the primary target of BRD9876, which interestingly is inhibitory only on microtubule-bound Eg5. This article is a great example of how cell-based HTS assays need to (i) exploit a defined physiologic phenotype, (ii) have a robust readout parameter, (iii) be complemented by counter screen assays to judge selectivity, and (iv) be followed by target identification studies and mechanism of action studies.
New Frontiers for HTS in Probe Discovery
A successful high-throughput screening campaign can yield multiple high quality hits, but this outcome is largely dependent on the content of the chemical library being screened, therefore placing a high level of importance on library design and selection. [41] [42] [43] Selected high-value assay positives identified using HTS can be promoted for development into a high quality probe with sufficient potency and selectivity. [1] This development stage can be cumbersome with the difficulty closely related to target biology and the chemical features of the small molecule. Moreover understanding the mechanism of action is a vital component in understanding the biological outcome. Therefore probe development campaigns are often lengthy and resource intensive. To overcome some of these obstacles, the HTS field must continue the development of HTS assays with higher information content, including those that may combine defined binding events with robust measurable functional activity. Development of physiologically relevant cell-based or biochemical assays will benefit tremendously from the deep understanding of biological activity of the target or pathway in question as well as the fine characterization of a unique disease-specific phenotype. Finally, technologies to assist demonstration of target engagement in cells, evaluating cellular specificity profiles, and uncovering precise mechanism of action are needed to define probe quality and to leverage the probe for systems-level studies.
As new genetic tools continue to develop and large gene expression data sets are being constructed, we witness an exponential increase in using computational means to link a cellular response of a novel molecule to the cellular profiles of known molecules. Using such powerful comparisons will certainly reduce the number of potential targets, prioritize hypothesis testing of mechanism of action and add valuable information related to specificity and potential off-target toxicity.
To further improve the power of primary HTS assays using pure proteins or cell lysates, it would behoove us to explore how we might leverage innovative methods for labeling proteins and other biomolecules using nucleic acid sequences and/or peptide sequences [45] [46] [47] [48] possibly allowing a multiplexed screening campaign to detect unique binding events through high fidelity target identification when screening compound collections in the presence of multiple relevant targets.
For phenotypic assays, thinking of integrating target ID into a primary screen might involve bridging compound treatments directly to mass spectrometry (MS) to identify targets engaged by phenotypically active molecules. Chemical moieties for covalent tethering of a molecule to its target or for target pull down upstream of MS analysis are commonly coupled to HTS hit compounds in follow-up studies, but devising clever ways to functionalize a relatively large library with these moieties in a manner that does not bias hits towards more reactive species or prevent target engagement through steric hindrance are worth exploring in high-throughput assay development. [49, 50] In closing, the chemical biology community has made tremendous advances in the area of high throughput screening for chemical probe discovery. We are encouraged by the combinations of established principles to provide higher-content information in primary assays and the adaptations of venerated platforms to accommodate diverse target classes. We expect to see a further increase in the development of higher-content HTS assays. This will significantly influence our campaigns for probe discovery and will further our understanding of unexamined biology for therapeutic development. 
